BUZZ-Incyte rises after lifting blood cancer drug sales forecast
I'm PortAI, I can summarize articles.
Shares of drugmaker Incyterise 4.5% to $73.3 premarketINCY raises its annual sales forecast for its blood cancer treatment, Jakafi, to a range between $3 billion and $3.05 billion, from its prior forecast of $2.95 billion to $3 billion Company posts Q2 adjusted profit of $1.57 per share, beating analysts’ estimate of $1.47 per share, according to data compiled by LSEGReports total revenue of $1.22 billion for the quarter, versus estimate of $1.15 billionUp to last close, stock up 1.6% YTD
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments